Advances in antibody-based therapy in oncology

被引：100
作者：
Zinn, Sacha [1 ,2 ]
Vazquez-Lombardi, Rodrigo [1 ,2 ,7 ]
Zimmermann, Carsten [3 ,4 ]
Sapra, Puja [5 ]
Jermutus, Lutz [6 ]
Christ, Daniel [1 ,2 ]
机构：
[1] Garvan Inst Med Res, Sydney, NSW, Australia
[2] Univ New South Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia
[3] Univ San Diego, Knauss Sch Business, San Diego, CA USA
[4] Univ Calif San Diego, La Jolla, CA USA
[5] AstraZeneca, Oncol R&D, Biol Engn & Targeted Delivery, Gaithersburg, MD USA
[6] Res & Early Dev, AstraZeneca, BioPharmaceut R&D, Cambridge, England
[7] Engimmune Therapeut, Allschwil, Switzerland
来源：
NATURE CANCER | 2023年 / 4卷 / 02期
基金：
英国医学研究理事会;
关键词：
C-RECEPTOR POLYMORPHISMS; I-RELATED RECEPTOR; T-CELL EXHAUSTION; SERUM HALF-LIFE; FC-GAMMA-RIIB; MONOCLONAL-ANTIBODY; DEPENDENT MECHANISMS; ANTITUMOR IMMUNITY; AGONISTIC ANTIBODY; EFFECTOR FUNCTIONS;
D O I：
10.1038/s43018-023-00516-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this review article, Christ and colleagues discuss the recent developments in antibody-based cancer therapies. Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineered antibody therapeutic candidates, discuss molecular structure and mechanisms of action and provide updates on clinical development and practice.
引用
收藏
页码：165 / 180
页数：16
相关论文
共 200 条
  • [1] Podocytes use FcRn to clear IgG from the glomerular basement membrane
    Akilesh, Shreeram
    Huber, Tobias B.
    Wu, Hui
    Wang, Gary
    Hartleben, Bjoern
    Kopp, Jeffrey B.
    Miner, Jeffrey H.
    Roopenian, Derry C.
    Unanue, Emil R.
    Shaw, Andrey S.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (03) : 967 - 972
  • [2] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [3] Neutrophils mediate antibody-induced antitumor effects in mice
    Albanesi, Marcello
    Mancardi, David A.
    Joensson, Friederike
    Iannascoli, Bruno
    Fiette, Laurence
    Di Santo, James P.
    Lowell, Clifford A.
    Bruhns, Pierre
    [J]. BLOOD, 2013, 122 (18) : 3160 - 3164
  • [4] The multifaceted role of TRAIL signaling in cancer and immunity
    Alves, Ludmila Cardoso
    Corazza, Nadia
    Micheau, Olivier
    Krebs, Philippe
    [J]. FEBS JOURNAL, 2021, 288 (19) : 5530 - 5554
  • [5] Role of ErbB Receptors in Cancer Cell Migration and Invasion
    Appert-Collin, Aline
    Hubert, Pierre
    Cremel, Gerard
    Bennasroune, Amar
    [J]. FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [6] Trastuzumab Emtansine: First Global Approval
    Ballantyne, Anita
    Dhillon, Sohita
    [J]. DRUGS, 2013, 73 (07) : 755 - 765
  • [7] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) : 1529 - 1541
  • [8] Cleavable linkers in antibody-drug conjugates
    Bargh, Jonathan D.
    Isidro-Llobet, Albert
    Parker, Jeremy S.
    Spring, David R.
    [J]. CHEMICAL SOCIETY REVIEWS, 2019, 48 (16) : 4361 - 4374
  • [9] Baselga J, 2001, Ann Oncol, V12 Suppl 1, pS35
  • [10] Strategies and challenges for the next generation of antibody drug conjugates
    Beck, Alain
    Goetsch, Liliane
    Dumontet, Charles
    Corvaia, Nathalie
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) : 315 - 337
12345678910